Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know
Eli Lilly and Co enters a critical period of expanding diet drug production, welcoming a new CFO.
US pharmaceutical giant Eli Lilly and Co. announced that Lucas Montarce, a senior financial expert within the company, has been appointed as the Chief Financial Officer, and the appointment is effective immediately. This personnel change comes at a critical moment as Eli Lilly is investing billions of dollars to expand production to meet the increasing demand for its diabetes and weight loss drugs (such as Mounjaro and Zepbound). Despite FDA approval, Eli Lilly still faces supply shortages.
A Glimpse Into The Expert Outlook On Eli Lilly Through 28 Analysts
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Eli Lilly (NYSE:LLY) Sheds 6.0% This Week, as Yearly Returns Fall More in Line With Earnings Growth
Is Eli Lilly and Company (LLY) a Good Big Company Stock to Buy Now?
